Tirzepatide vs. semaglutide: clinical decision-making in the GLP-1 landscape

20250 citationsJournal Article

Authors

Alvin Mondoh · University College Dublin

Michael Crotty · Oregon Weight Loss Surgery

Carel W. le Roux · Oregon Weight Loss Surgery

Abstract

Semaglutide and tirzepatide represent foundational options in contemporary obesity pharmacotherapy. Semaglutide offers robust cardiovascular protection; tirzepatide yields greater weight loss and broad metabolic benefits. Both agents require clinicians to reconceptualize obesity as a chronic disease needing ongoing pharmacological management.

Topics & Keywords

Diabetes Treatment and Management Pharmacology and Obesity Treatment Bariatric Surgery and Outcomes

Publication Details

Published in: Expert Opinion on Pharmacotherapy

Volume 26, Issue 17, pp. 1841-1854

DOI: 10.1080/14656566.2025.2601060

Field-Weighted Citation Impact: 0.00

Command Palette

Tirzepatide vs. semaglutide: clinical decision-making in the GLP-1 landscape

Authors

Abstract

Topics & Keywords

Publication Details